CMFRI has earned a patent for anti-dyslipidemic nutraceutical (Patent Number 376296) from seaweed
A patent has been granted to ICAR-CMFRI for an invention entitled “A process to prepare anti-dyslipidemic concentrate from seaweed and a product therof” (Patent Number 376296) for the term of 20 years from the 29th day of May 2017 in accordance with the provisions of the Patents Act, 1970. CadalminTMACe is an anti-dyslipidemic nutraceutical, which is effective to combat dyslipidemia. It contains 100% natural marine bioactive ingredients extracted from selected seaweeds. The bioactive ingredients in CadalminTMACe competitively inhibit hydroxymethyl glutaryl coenzyme A reductase, various target receptors and other rate limiting enzymes, thereby hindering the occurrence of dyslipidemia. The active ingredients also attenuate high fat-induced hyperlipidemia, characterized by significantly lower level of serum LDL, lipid peroxidation status and lower atherogenic index. CadalminTMACe has no side effects as proved from the long-term toxicity studies. The active ingredients purified and concentrated; a total of 350 mg active ingredients in the product are packed in plant-based capsules (cellulose-based hypermelose) to meet the dietary needs of vegetarians. The technology was commercialized during 2017 for commercial production and marketing.
CMFRI adjudged as best research institute under ICAR
CMFRI wins ICAR’s highest award
The Central Marine Fisheries Research Institute (CMFRI) has been adjudged as the best research institute of the Indian Council of Agricultural Research (ICAR). The CMFRI won the Sardar Patel Outstanding ICAR institutions award, the highest award of the ICAR in the category of the large institutions with a cash prize of Rs 10 Lakhs, a Silver Plaque, Certificate and Citation.This is in recognition of CMFRI’s excellent performance in marine fisheries research during the period from 2014 to 2019.